Bilanoa
• Very strong in H1, grow further in H2
• Gained an solid reputation from both patients and doctors
• Boost sales promotion
SYCREST
• Steady growth in H1 but below target
• Reorganize to establish sales structure suitable to promote drug for psychotic disorders
• Achieve sales target
REFLEX
• Mirtazapine, generic drug of REFLEX, will be available in December
• Sales rather uncertain due to harsh competition
• Meiji Seika Pharma to launch Mirtazapine to maintain share
Generic drugs
• Grow sales despite significant NHI drug price reduction
• Injectable antibacterial drugs such as TAZOPIPE remaining favorable
Influenza vaccine, Product of KM Biologics
• Started selling in September, JPY 3.0 billion in FYE March 2019
• Expand product line, vaccine and antibacterial drug – Cover preventive through treatment for infectious disease
• Expecting further synergy in sales and R&D
Domestic Business
Bilanoa
• Very strong in H1, grow further in H2
• Gained an solid reputation from both patients and doctors
• Boost sales promotion
SYCREST
• Steady growth in H1 but below target
• Reorganize to establish sales structure suitable to promote drug for psychotic disorders
• Achieve sales target
REFLEX
• Mirtazapine, generic drug of REFLEX, will be available in December
• Sales rather uncertain due to harsh competition
• Meiji Seika Pharma to launch Mirtazapine to maintain share
Generic drugs
• Grow sales despite significant NHI drug price reduction
• Injectable antibacterial drugs such as TAZOPIPE remaining favorable
Influenza vaccine, Product of KM Biologics
• Started selling in September, JPY 3.0 billion in FYE March 2019
• Expand product line, vaccine and antibacterial drug – Cover preventive through treatment for infectious disease
• Expecting further synergy in sales and R&D